Boehringer Ingelheim (BI) has inaugurated a new EUR 700-million ($809-million) large-scale, cell-culture biomanufacturing facility in Vienna, Austria.

With an investment of more than EUR 700-million ($809 million), it is the single largest investment in the company’s history. The facility will produce products from the company’s own product portfolio as well as for third-party contract manufacturing. The company’s global biopharmaceutical network has four manufacturing sites in Asia, Europe, and the US. 

The new facility adds 185,000 liters of biopharmaceutical production capacity to add an additional 30% to the company’s mammalian large-scale capacity. The new facility has created 500 new positions at the site in Vienna.

The plant is designed to allow changeovers from one product to another or simultaneous production of different products. Additionally, multi-product setup enables production of a large variety of molecule formats. The facility offers digitalization and automation through smart technologies and artificial intelligence applications.

Source: Boehringer Ingelheim